TOKYO, Japan - April 11th, 2022 - Medical Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that it has launched a five-test kit for lateral flow based rapid immunoassay, GLINE-2019-nCoV Ag Kit, for SARS-CoV-2 antigen detection.
Contact details
-
Download vCard
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
MBL Launches a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens
This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.
MBL Obtained European Quality Management System Certificate (IVDR)
The certification ensures that the CE marked diagnostic products supplied by MBL adhere to standards of quality and safety that ensure the highest level of patients’ health protection
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.